drugset
drugset / Trial / NCT04743934

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

NCT04743934 ↗

Phase 2 Completed 44 enrolled Andrew McDonald National Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.

Timeline

Start
2021-07-02
Primary completion
2025-03-01
Completion
2026-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject flibanserin Small molecule 100 mg Oral

Indications

prostate adenocarcinoma